Sign up USA
Proactive Investors - Run By Investors For Investors

Bristol-Myers Squibb to get keys to Padlock

Bristol-Myers Squibb Company is to snap up Padlock Therapeutics
Bristol-Myers Squibb to get keys to Padlock
Bristol-Myers Squibb to buy Padlock

Bristol-Myers Squibb Company (NYSE:BMY) is to snap up Padlock Therapeutics, it was announced on Wednesday.

The companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases.

The acquisition will give Bristol-Myers Squibb full rights to Padlock’s Protein/Peptidyl Arginine Deiminase (PAD) inhibitor discovery program focused on the development of potentially transformational treatment approaches for patients with rheumatoid arthritis (RA).

Padlock’s PAD discovery programme may have additional utility in treating systemic lupus erythematosus (SLE) and other autoimmune diseases.

Bristol-Myers shares closed down 0.73% at $62.34.



Register here to be notified of future BMY Company articles
View full BMY profile

Bristol Myers Squibb Timeline

Newswire
December 06 2016

Related Articles

Cells
January 06 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
Venn-Life.jpg
October 04 2016
Innovenn owns and is developing Labskin, a living skin model and also has an anti-acne formulation.
Benjamin Franklin wearing a medical mask
March 24 2016
Constellation has identified a significant market opportunity in healthcare billing management.
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC